Synergism and schedule dependent cytotoxicity of cyclophosphamide and ccnu in experimental cancer chemotherapy
article
A synergistic degree of cell killing was obtained with cyclophosphamide and CCNU in the L1210 leukemia, the Lewis lung carcinoma and the mouse C22LR osteosarcoma. Drug synergism was also demonstrated in both resting and rapidly proliferating haemopoietic stem cells. By scheduling the 2 drugs we attempted to obtain selective cell kill of tumour cells over vital normal cells. The optimum antitumour schedule was found to be that when the drugs were given simultaneously. This tumor based schedule however, proved to be the most toxic for bone marrow stem cells as well. Therefore, the clinical relevance of this synergistic drug combination is expected to be limited.
Chemicals/CAS: cyclophosphamide, 50-18-0; lomustine, 13010-47-4; Cyclophosphamide, 50-18-0; Lomustine, 13010-47-4; Nitrosourea Compounds
Chemicals/CAS: cyclophosphamide, 50-18-0; lomustine, 13010-47-4; Cyclophosphamide, 50-18-0; Lomustine, 13010-47-4; Nitrosourea Compounds
Topics
cyclophosphamidelomustineanimal experimentblood and hemopoietic systembonecancer chemotherapycancer graftcell culturecytotoxicitydrug comparisondrug potentiationdrug toxicityhematopoietic cellin vitro studyintoxicationleukemia cellleukemia l 1210lewis carcinomamouseosteosarcomarespiratory systemAnimalCell SurvivalCyclophosphamideDrug Administration ScheduleDrug SynergismDrug Therapy, CombinationHematopoietic Stem CellsIn VitroLomustineMiceNeoplasms, ExperimentalNitrosourea Compounds
TNO Identifier
228412
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 14(5), pp. 537-542.
Pages
537-542
Files
To receive the publication files, please send an e-mail request to TNO Repository.